Lionco Pharmaceutical Group Co.,Ltd.

603669

CNE1000022R8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 19/05/2024 BST			5-day change	1st Jan Change
4.97 ^CNY	+1.22%		0.00%	-10.13%

04-19	Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01-31	Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	CI

Lionco Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.

January 28, 2023

The Board of Directors of Lionco Pharmaceutical Group Co.,Ltd. has authorized a buyback plan on January 29, 2023.

Latest news about Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	01-30	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on January 31, 2023, has closed with 8,785,900 shares, representing 1.22% for CNY 50 million.	01-27	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	01-02	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	11-13	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	11-13	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	11-13	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	20/10/23	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Lionco Pharma Registers Latamoxef Sodium for Injection in China	04/08/23	MT
Lionco Pharma's Bacterial Drug Passes Regulator's Evaluation	21/06/23	MT
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	21/04/23	CI
Lionco Pharma Unit's Aztreonam for Injection Passes Drug Regulator's Evaluation	18/04/23	MT
Lionco Pharma to Raise Up to 100 Million Yuan Through Share Buyback	31/01/23	MT
Lionco Pharmaceutical Group Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	30/01/23	CI
Lionco Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	28/01/23	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	10/01/23	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on March 10, 2022 has closed with 8,915,893 shares, for CNY 60 million.	08/01/23	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	05/01/23	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	10/10/22	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	26/08/22	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	04/07/22	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22	CI

Chart Lionco Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Lionco Pharmaceutical Group Co.,Ltd.

More charts

Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.

Sector

Pharmaceuticals

Calendar

14/06/2024 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LIONCO PHARMACEUTICAL GROUP CO.,LTD.	-10.13%	478M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.12B
OTSUKA HOLDINGS CO., LTD.	+22.99%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.61B
ZYDUS LIFESCIENCES LIMITED	+60.18%	13.34B
ONO PHARMACEUTICAL CO., LTD.	-8.35%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.65%	5.63B